By Scientia Professor Gregory John Dore

Journal articles

Jacka B; Lamoury F; Simmonds P; Dore GJ; Grebely J; Applegate T, 2013, 'Sequencing of the Hepatitis C Virus: A Systematic Review', PLoS ONE, 8, pp. e67073, http://dx.doi.org/10.1371/journal.pone.0067073

Grebely J; Feld JJ; Applegate T; Matthews GV; Hellard M; Sherker A; Petoumenos K; Zang G; Shaw I; Yeung B; George J; Teutsch S; Kaldor JM; Cherepanov V; Bruneau J; Shoukry NH; Lloyd AR; Dore GJ, 2013, 'Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection', Hepatology, 57, pp. 2124 - 2134, http://dx.doi.org/10.1002/hep.26263

Deans GD; Raffa JD; Lai C; Fischer B; Krajden M; Amin J; Walter SR; Dore GJ; Grebely J; Tyndall MW, 2013, 'Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada', CMAJ Open, 1, pp. e68 - e76, http://dx.doi.org/10.9778/cmajo.20130002

Hegerle N; Rayat L; Dore G; Zidane N; Bedouelle H; Guiso N, 2013, 'In-vitro and in-vivo analysis of the production of the Bordetella type three secretion system effector A in Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica', Microbes and Infection, 15, pp. 399 - 408, http://dx.doi.org/10.1016/j.micinf.2013.02.006

Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2013, 'Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment', Journal of Gastroenterology and Hepatology (Australia), 28, pp. 1770 - 1781, http://dx.doi.org/10.1111/jgh.12265

Grebely J; Oser ML; Taylor L; Dore GJ, 2013, 'Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: Action required at the system, provider, and patient levels', Journal of Infectious Diseases, 207, pp. S19 - S25, http://dx.doi.org/10.1093/infdis/jis928

Suppiah V; Armstrong NJ; O'Connor KS; Berg T; Weltman M; Abate ML; Spengler U; Bassendine M; Dore GJ; Irving WL; Powell E; Nattermann J; Mueller T; Riordan S; Stewart GJ; George J; Booth DR; Ahlenstiel G; Michalk M; Malik B; McClure P; Smith S; Sheridan D; Snape E; Fragomeli V; Norris R; How-Chow D; Jonsson JR; Barrie H; Stelzer-Braid S; Fletcher S; Applegate T; Grebely J; Matthews G; Bharadwaj M; Smedile A, 2013, 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection', Genes and Immunity, 14, pp. 286 - 290, http://dx.doi.org/10.1038/gene.2013.15

Post J; Arain A; Lloyd AR; Grebely J; Dore G, 2013, 'Enhancing Assessment and Treatment Hepatitis C in the Custodial Setting', Clinical Infectious Diseases, 57, pp. S70 - S74, http://dx.doi.org/10.1093/cid/cit264

Matthews G; Seaberg E; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz JJ; Revill PA; Littlejohn M; Hoy J; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio C, 2013, 'Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus', Clinical Infectious Diseases, 56, pp. e87 - e94, http://dx.doi.org/10.1093/cid/cit002

Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond RA; Bowden S; Lewin SR; Sasadeusz JJ; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ, 2013, 'Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals', PLoS One, 8, pp. e61297, http://dx.doi.org/10.1371/journal.pone.0061297

Jacobson IM; Dore GJ; Foster G; Fried MW; Radu MN; Rafalskiy VV; Moroz L; Craxi; ag A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Kalmeijer R; Beumont-Mauviel M, 2013, 'Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial', Gastroenterology, 144, pp. S - 374, http://dx.doi.org/10.1016/s0016-5085(13)61381-5

Kitson MT; Dore GJ; George J; Button P; McCaughan G; Crawford D; Sievert W; Weltman M; Cheng W; Robertson S, 2013, 'Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection', Journal of Hepatology, 58, pp. 467 - 472, http://dx.doi.org/10.1016/j.jhep.2012.11.017

Hellard M; Grebely J; Yeung B; Dore G; Marks P; Shaw D; Byrne M; Matthews G, 2012, 'EFFECTIVENESS OF RESPONSE-GUIDED THERAPY IN RECENT HEPATITIS C INFECTION: THE AUSTRALIAN TRIAL IN ACUTE HEPATITIS C', DRUG AND ALCOHOL REVIEW, 31, pp. 33 - 33

Grebely J; Alavi M; Spelman T; Haber P; Day C; Matthews G; Van Beek I; Walsh N; Yeung B; Petoumenos K; Dolan K; Kaldor J; Dore G; Hellard M, 2012, 'IMPACT OF TREATMENT OF RECENTLY-ACQUIRED HEPATITIS C INFECTION ON INJECTING DRUG USE BEHAVIOURS', DRUG AND ALCOHOL REVIEW, 31, pp. 34 - 34

Holmes JA; Bonanzinga S; Roberts S; Sievert W; Dore G; Mccaughan G; Crawford DH; Cheng W; Weltman MD; Matthews G; Visvanathan K; Desmond P; Bowden DS; Thompson A, 2012, 'ITPA genotype strongly protects from ribavirin-induced haemolytic anaemia: analysis from the CHARIOT study', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27, pp. 168 - 168

Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N, 2012, 'Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: Increase of Bordetellae not expressing pertactin', Clinical Microbiology and Infection, 18, http://dx.doi.org/10.1111/j.1469-0691.2012.03925.x

White BA; Dore GJ; Lloyd AR; Rawlinson WD; Maher L, 2012, 'Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney', Australian and New Zealand Journal of Public Health, 36, pp. 351 - 356, http://dx.doi.org/10.1111/j.1753-6405.2012.00881.x

Cowie BC; Dore GJ, 2012, 'The Perpetual Challenge of Infectious Diseases', New England Journal of Medicine, 367, pp. 89 - 89, http://dx.doi.org/10.1056/nejmc1204960

Avihingsanon A; Matthews GV; Lewin SR; Marks P; Sasadeusz JJ; Cooper DA; Bowden S; Locarnini SA; Dore GJ; Ruxrungtham K, 2012, 'Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand', AIDS Research and Therapy, 9, pp. Article number 6, http://dx.doi.org/10.1186/1742-6405-9-6

Hajarizadeh B; Grebely J; Dore GJ, 2012, 'Case definitions for acute hepatitis C virus infection: A systematic review', Journal of Hepatology, 57, pp. 1349 - 1360, http://dx.doi.org/10.1016/j.jhep.2012.07.007

Grebely J; Morris M; Rice T; Bruneau J; Cox AL; Kim A; McGovern B; Shoukry N; Lauer G; Maher L; Lloyd AR; Hellard M; Prins M; Dore GJ; Page K, 2012, 'Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study.', International Journal of Epidemiology, in press, pp. 1-11, http://dx.doi.org/10.1093/ije/dys167

Crawford DHG; Dore GJ; Sievert W; Cheng WSC; Weltman M; McCaughan G; Rawlinson WD; Marks P; Yoshihara M; Rizkalla B; Roberts SK, 2012, 'Early on-treatment viral load and baseline METAVIR score: Improved prediction of sustained virological response in HCV genotype 1 patients', Antiviral Therapy, 17, pp. 849 - 854, http://dx.doi.org/10.3851/IMP2104

Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Beek IV; Kaldor JM; Hellard M; Dore GJ; Haber PS; Alavi M; Van Beek I; Amin J; Dolan K; Rawlinson W; Flynn J; Marks P; Acraman B; Bloch M; Li H; Madden A; George J, 2012, 'Effect of pegylated interferon-a-2a treatment on mental health during recent hepatitis C virus infection', Journal of Gastroenterology and Hepatology, 27, pp. 957 - 965, http://dx.doi.org/10.1111/j.1440-1746.2011.07035.x

Kwon J; Anderson JS; Kerr CC; Thein H; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP; Han A, 2012, 'Estimating the cost-effectiveness of needle-syringe programs in Australia.', AIDS, 26, pp. 2201 - 2210, http://dx.doi.org/10.1097/QAD.0b013e3283578b5d

Gidding HF; Law MG; Amin J; Ostapowicz G; Weltman MD; Macdonald GAM; Sasadeusz JJ; Haber PS; George J; Dore GJ; Han A, 2012, 'Hepatitis C treatment outcomes in Australian clinics', Medical Journal of Australia, 196, pp. 633 - 637, http://dx.doi.org/10.5694/mja12.10014

Grebely J; Prins M; Hellard M; Cox AL; Osburn WO; Lauer G; Page K; Lloyd AR; Dore GJ; Maher L, 2012, 'Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine', Lancet Infectious Diseases, 12, pp. 408 - 414, http://dx.doi.org/10.1016/S1473-3099(12)70010-5

Grebely J; Pham ST; Matthews G; Petoumenos K; Bull RA; Yeung B; Rawlinson WD; Kaldor JM; Lloyd AR; Hellard M; Dore GJ; White PA; Bull ; Dolan K, 2012, 'Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection', Hepatology, 55, pp. 1058 - 1069, http://dx.doi.org/10.1002/hep.24754

Flynn J; Dore GJ; Matthews G; Hellard M; Yeung B; Rawlinson W; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2012, 'Impaired hepatitis C virus (HCV)-specific interferon-responses in individuals with HIV who acquire HCV infection: Correlation with CD4 + T-cell counts', Journal of Infectious Diseases, 206, pp. 1568 - 1576, http://dx.doi.org/10.1093/infdis/jis544

Treloar C; Hull PB; Dore GJ; Grebely J, 2012, 'Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs', Drug and Alcohol Review, 31, pp. 918 - 924, http://dx.doi.org/10.1111/j.1465-3362.2012.00468.x

Thein H; Walter SR; Gidding HF; Amin J; Law MG; George J; Dore GJ; Han A, 2012, 'Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort', Hepatology Research, 42, pp. 1175 - 1186, http://dx.doi.org/10.1111/j.1872-034X.2012.01037.x

Dore GJ, 2012, 'The changing therapeutic landscape for hepatitis C.', Medical Journal of Australia, 196, pp. 629 - 632, http://dx.doi.org/10.5694/mja11.11531

Vickerman P; Grebely J; Dore GJ; Sacks-davis R; Page K; Thomas DL; Osburn WO; Cox AL; Aitken CL; Hickman M; Hellard M; Maher L, 2012, 'The more you look, the more you find: Effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design', Journal of Infectious Diseases, 205, pp. 1342 - 1350, http://dx.doi.org/10.1093/infdis/jis213

Grebely J; Hellard M; Applegate TL; Petoumenos K; Yeung B; Feld J; Rawlinson WD; Lloyd AR; George J; Kaldor JM; Dore GJ; Matthews G; Dolan K, 2012, 'Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection', AIDS, 26, pp. 1653 - 1661, http://dx.doi.org/10.1097/QAD.0b013e3283553719

Grebely J; Dore GJ, 2012, 'What is killing people with hepatitis C virus infection?', Seminars in Liver Disease, 31, pp. 331 - 339, http://dx.doi.org/10.1055/s-0031-1297922

Matthews GV; Dore GJ, 2011, 'HIV and Hepatitis C Co-Infection', , pp. 177 - 184, http://dx.doi.org/10.1002/9781444346343.ch22

Ewer P; Mills K; Teesson M; Sannibale C; Baker A; Kay-Lambkin F; Dore G, 2011, 'A BRIEF INTERVENTION FOR ALCOHOL AND OTHER DRUG USERS WHO HAVE EXPERIENCED TRAUMA', DRUG AND ALCOHOL REVIEW, 30, pp. 29 - 29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000297019700088&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Peters L; Neuhaus J; Mocroft A; Soriano V; Rockstroh J; Dore G; Puoti M; Tedaldi E; Clotet B; Kupfer B; Lundgren JD; Klein MB, 2011, 'Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART study', Antiviral Therapy, 16, pp. 667 - 675, http://dx.doi.org/10.3851/IMP1815

Sievert W; Dore GJ; Roberts SK, 2011, 'Reply', Hepatology, 53, pp. 1775 - 1776, http://dx.doi.org/10.1002/hep.24250

Matthews GV; Dore GJ, 2011, 'Optimal duration of treatment for acute hepatitis c in human immunodeficiency virus-positive individuals?', Hepatology, 53, pp. 1055 - 1056, http://dx.doi.org/10.1002/hep.24152

Bouchez V; Brun D; Dore G; Njamkepo E; Guiso N, 2011, 'Bordetella parapertussis isolates not expressing pertactin circulating in France', Clinical Microbiology and Infection, 17, pp. 675 - 682, http://dx.doi.org/10.1111/j.1469-0691.2010.03303.x

Grebely J; Matthews G; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber P; Lloyd AR; Kaldor JM; Dore GJ; Dolan K, 2011, 'Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users', Journal of Hepatology, 55, pp. 76 - 85, http://dx.doi.org/10.1016/j.jhep.2010.10.033

Grebely J; Dore GJ, 2011, 'An expanding role for primary care providers in the treatment of hepatitis C virus infection in the community', Hepatology, 54, pp. 2259 - 2261

Sasadeusz J; Dore GJ; Kronborg I; Barton D; Yoshihara M; Weltman M, 2011, 'Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy', Addiction, 106, pp. 977 - 984, http://dx.doi.org/10.1111/j.1360-0443.2010.03347.x

Flynn JK; Dore GJ; Hellard M; Yeung B; Rawlinson WD; White PA; Kaldor JM; Lloyd AR; Ffrench RA; Dolan K, 2011, 'Early IL-10 predominant responses are associated with progression from acute to chronic hepatitis C virus infection in injecting drug users', Journal of Viral Hepatitis, 18, pp. 549 - 561, http://dx.doi.org/10.1111/j.1365-2893.2010.01335.x

Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S, 2011, 'Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients', Antiviral Therapy, 16, pp. 173 - 180, http://dx.doi.org/10.3851/IMP1731

Audsley J; Seaberg E; Sasadcusz J; Matthews G; Avihingsanon A; Ruxrungtham K; Fairley K; Finlayson RJ; Hwang H; Littlejohn M; Locarnini S; Dore GJ; Thio C; Lewin S, 2011, 'Factors associated with elevated ALT in an international HIV/HBV Co-Infected cohort on long-term HAART', PLoS One, 6, pp. e26482, http://dx.doi.org/10.1371/journal.pone.0026482

Grebely J; Bryant J; Hull PB; Hopwood MN; Lavis YM; Dore GJ; Treloar C, 2011, 'Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.', Journal of Viral Hepatitis, 18, pp. 104 - 116, http://dx.doi.org/10.1111/j.1365

Dore GJ; Matthews GV; Rockstroh J, 2011, 'Future of hepatitis C therapy: Development of direct-acting antivirals', Current opinion in HIV & AIDS, 6, pp. 508 - 513, http://dx.doi.org/10.1097/COH.0b013e32834b87f8

Grebely J; Dore GJ, 2011, 'Hepatitis C: Enhancing treatment for hepatitis C among drug users', Nature Reviews Gastroenterology and Hepatology, 8, pp. 11 - 13, http://dx.doi.org/10.1038/nrgastro.2010.186

Gidding HF; Amin J; Dore GJ; Law MG, 2011, 'Hospitalization rates associated with hepatitis B and HIV co-infection, age and sex in a population-based cohort of people diagnosed with hepatitis C', Epidemiology and Infection, 139, pp. 1151 - 1158

Back to profile page